首页> 美国卫生研究院文献>other >A Meta-Analysis Approach for Characterizing Pan-Cancer Mechanisms of Drug Sensitivity in Cell Lines
【2h】

A Meta-Analysis Approach for Characterizing Pan-Cancer Mechanisms of Drug Sensitivity in Cell Lines

机译:表征细胞系药物敏感性泛癌机制的Meta分析方法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Understanding the heterogeneous drug response of cancer patients is essential to precision oncology. Pioneering genomic analyses of individual cancer subtypes have begun to identify key determinants of resistance, including up-regulation of multi-drug resistance (MDR) genes and mutational alterations of drug targets. However, these alterations are sufficient to explain only a minority of the population, and additional mechanisms of drug resistance or sensitivity are required to explain the remaining spectrum of patient responses to ultimately achieve the goal of precision oncology. We hypothesized that a pan-cancer analysis of in vitro drug sensitivities across numerous cancer lineages will improve the detection of statistical associations and yield more robust and, importantly, recurrent determinants of response. In this study, we developed a statistical framework based on the meta-analysis of expression profiles to identify pan-cancer markers and mechanisms of drug response. Using the Cancer Cell Line Encyclopaedia (CCLE), a large panel of several hundred cancer cell lines from numerous distinct lineages, we characterized both known and novel mechanisms of response to cytotoxic drugs including inhibitors of Topoisomerase 1 (TOP1; Topotecan, Irinotecan) and targeted therapies including inhibitors of histone deacetylases (HDAC; Panobinostat) and MAP/ERK kinases (MEK; PD-0325901, AZD6244). Notably, our analysis implicated reduced replication and transcriptional rates, as well as deficiency in DNA damage repair genes in resistance to TOP1 inhibitors. The constitutive activation of several signaling pathways including the interferon/STAT-1 pathway was implicated in resistance to the pan-HDAC inhibitor. Finally, a number of dysregulations upstream of MEK were identified as compensatory mechanisms of resistance to the MEK inhibitors. In comparison to alternative pan-cancer analysis strategies, our approach can better elucidate relevant drug response mechanisms. Moreover, the compendium of putative markers and mechanisms identified through our analysis can serve as a foundation for future studies into these drugs.
机译:了解癌症患者的异种药物反应对精确肿瘤学至关重要。对个别癌症亚型的开拓性基因组分析已开始确定耐药性的关键决定因素,包括多药耐药性(MDR)基因的上调和药物靶点的突变。但是,这些改变仅足以解释少数人群,并且还需要其他抗药性或敏感性机制来解释患者反应的其余范围,以最终实现精确肿瘤学的目标。我们假设,对多种癌症谱系中的体外药物敏感性进行全癌分析,将改善对统计关联的检测,并产生更可靠且重要的复发反应决定因素。在这项研究中,我们基于表达谱的荟萃分析建立了一个统计框架,以确定泛癌标志物和药物反应机制。我们使用癌细胞系百科全书(CCLE)(来自众多不同谱系的数百个癌细胞系),对已知和新颖的细胞毒性药物反应机制(包括拓扑异构酶1抑制剂(TOP1; Topotecan,伊立替康))进行了特征分析和靶向包括组蛋白脱乙酰基酶抑制剂(HDAC; Panobinostat)和MAP / ERK激酶(MEK; PD-0325901,AZD6244)抑制剂。值得注意的是,我们的分析表明复制和转录速率降低,以及DNA损伤修复基因对TOP1抑制剂的抵抗力不足。包括干扰素/ STAT-1途径在内的几种信号途径的组成性激活与泛HDAC抑制剂的耐药性有关。最后,MEK上游的许多失调被鉴定为对MEK抑制剂的抗性的补偿机制。与其他泛癌分析策略相比,我们的方法可以更好地阐明相关的药物反应机制。此外,通过我们的分析确定的推定标记物和机制简编可以作为今后对这些药物进行研究的基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号